Making a case “for” focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Wang A. Z., Lebastchi A. H., O’Connor L. P., Ahdoot M., Mehralivand S., Yerram N., ...More

World Journal of Urology, vol.39, no.3, pp.729-739, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1007/s00345-020-03525-0
  • Journal Name: World Journal of Urology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Gender Studies Database, MEDLINE
  • Page Numbers: pp.729-739
  • Keywords: Focal therapy, prostate cancer, MRI
  • Istanbul Medipol University Affiliated: Yes

Abstract

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical “middle ground” in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.